1
Clinical Trials associated with GSK-1827771A Phase I, Randomized, Observer- and Subject-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1827771 in Healthy Volunteers
GSK182771 is a domain antibody targeting the interleukin (IL)-1 receptor which is being developed for the treatment of rheumatoid arthritis. This study is being done in healthy volunteers to verify the safety and tolerability of GSK182771
100 Clinical Results associated with GSK-1827771
100 Translational Medicine associated with GSK-1827771
100 Patents (Medical) associated with GSK-1827771
100 Deals associated with GSK-1827771